W
WAVEMAN · COMPANY
FDMT · 4D Molecular Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

FDMT

4D Molecular Therapeutics, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001650648
FORM 144 · 10☆ WATCH
INSIDER NET · 180D
-$3.7M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
98
13F, latest reported quarter
REVENUE GROWTH
+230194.6%
XBRL, annual
NET MARGIN
-164.4%
CONVERSIONS · 180D
9
codes C/M, not in net · $305.6K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$3.7M over 180 days
-$3.7M over 90 days
below 75% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
98 funds added or opened last quarter
more than 64% of Pharma & Biotech
REVENUE
+230194.6% year over year
the highest in Pharma & Biotech
MARGIN
-164.4% net margin
below 70% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
24.2% of shares outstanding short · 17.7 days to cover · settled 2026-07-31
more than 98% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$3.7M across 3 people in 180 days.
98 funds added or opened positions in the latest 13F quarter, of 161 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +139.4%
+139.4%12M
+0%+58%+115%+173%2025-092025-102025-122026-032026-052026-072026-09 2026-06-22 · Kirn David sold $1.2M2026-08-19 · Kirn David sold $662.6K2026-07-09 · Kirn David sold $548.2K2026-08-19 · Kirn David sold $425.7K2026-08-04 · Kirn David sold $274.6K2026-07-10 · Kirn David sold $183.6K2026-08-03 · Kirn David sold $124.7K2026-06-23 · Bizily Scott sold $117.7K2026-06-30 · Bizily Scott sold $91.9K2025-10-24 · Bizily Scott sold $32.1K2025-10-09 · Bizily Scott sold $24.1K2026-08-17 · Bizily Scott sold $19.9K2026-08-13 · Bizily Scott sold $19.6K2026-06-01 · Kirn David sold $19.3K2025-09-23 · Bizily Scott sold $19.3K2025-12-16 · Bizily Scott sold $17.8K2025-11-17 · Bizily Scott sold $17.3K2025-10-16 · Bizily Scott sold $16.6K2026-09-01 · Bizily Scott sold $8.2K2026-07-10 · Kirn David sold $5.7K2025-12-20 · Gupta Ashoo sold $2.7K2026-03-20 · Gupta Ashoo sold $2.7K2026-03-20 · Gupta Ashoo sold $6892025-12-20 · Gupta Ashoo sold $6862026-08-19 · David Kirn filed to sell $1.2M2026-08-17 · SCOTT BIZILY filed to sell $79.7K2026-08-13 · SCOTT BIZILY filed to sell $19.4K2026-08-04 · David Kirn filed to sell $275.4K2026-08-03 · David Kirn filed to sell $125.3K2026-07-10 · David Kirn filed to sell $193.6K2026-07-09 · David Kirn filed to sell $549.2K2026-06-30 · SCOTT BIZILY filed to sell $84.6K2026-06-23 · SCOTT BIZILY filed to sell $102.2K2026-06-22 · David Kirn filed to sell $1.2M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $3.7M sold by insiders over 180 days, 98 funds added last quarter, $3.8M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, 4D Molecular Therapeutics, Inc. insiders sold a net $3.7M of stock across 88 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Bizily Scott
Chief Legal Officer
SELL
2026-09-01
584.0
$8.2K
Kirn David
See Remarks
SELL
2026-08-19
43,149.0
$662.6K
Kirn David
See Remarks
SELL
2026-08-19
25,927.0
$425.7K
Bizily Scott
Chief Legal Officer
SELL
2026-08-17
1,635.0
$19.9K
Bizily Scott
Chief Legal Officer
SELL
2026-08-13
1,635.0
$19.6K
88 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 83 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Jupiter Topco LLC
5,746,289.0 sh
$76.5M
RA CAPITAL MANAGEMENT, L.P.
5,049,779.0 sh
$67.2M
BlackRock, Inc.
4,546,059.0 sh
$60.5M
GOLDMAN SACHS GROUP INC
4,258,668.0 sh
$56.6M
NOVO HOLDINGS A/S
3,249,178.0 sh
$43.2M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
David Kirn
FILED 2026-08-19
$1.2M
SCOTT BIZILY
FILED 2026-08-17
$79.7K
SCOTT BIZILY
FILED 2026-08-13
$19.4K
David Kirn
FILED 2026-08-04
$275.4K
David Kirn
FILED 2026-08-03
$125.3K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Simplify Propel Opportunities ETF
$655.7K POSITION · AS OF 2026-03-31
0.9%
Federated Hermes MDT Small Cap Value Fund f/k/a Federated Hermes Clover Small Value Fund
$984.7K POSITION · AS OF 2026-03-31
0.7%
Virtus Biotech Clinical Trials Etf
$225.8K POSITION · AS OF 2026-04-30
0.6%
Ultra-Small Company Market Fund
$465.5K POSITION · AS OF 2026-03-31
0.4%
Federated Hermes MDT Small Cap Core ETF
$378.8K POSITION · AS OF 2026-02-28
0.2%
Federated Hermes MDT Small Cap Core Fund
$4.2M POSITION · AS OF 2026-04-30
0.2%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 9 registered trials, 9 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
1 ACTIVE
2
Phase 2
2 ACTIVE
2
Phase 3
2 ACTIVE
4
Multi-phase
4 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$85.2M$37.0K$20.7M$3.1M
OPERATING INCOME$-159.5M$-187.8M$-112.9M$-110.0M
NET INCOME$-140.1M$-160.9M$-100.8M$-107.5M
EPS (DILUTED)-2.42-2.98-2.58-3.32
OPERATING CASH FLOW$-109.1M$-134.6M$-75.8M$-86.7M
CASH$60.2M$149.3M$249.1M$52.4M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →